Related Experiment Video

Updated: Jun 2, 2026

Culture Methods to Determine the Limit of Detection and Survival in Transport Media of Campylobacter Jejuni in Human Fecal Specimens
08:23

Culture Methods to Determine the Limit of Detection and Survival in Transport Media of Campylobacter Jejuni in Human Fecal Specimens

Published on: March 10, 2020

[Campylobacter in stool of patients with irritable bowel syndrome]

E A Burliaeva, A V Bulakhov, V I Pilipenko

    Eksperimental'Naia I Klinicheskaia Gastroenterologiia = Experimental & Clinical Gastroenterology
    |April 14, 2011
    PubMed
    Abstract

    Insights

    Campylobacter jejuni was detected in 5% of Russian irritable bowel syndrome (IBS) patients. Further research is needed to understand the role of gut microbiota in IBS, especially after acute enteric infections (AEI).

    Area of Science:

    • Microbiology
    • Gastroenterology
    • Infectious Diseases

    Background:

    • Irritable Bowel Syndrome (IBS) affects a significant portion of the population.
    • Acute enteric infections (AEI) are linked to a substantial prevalence of IBS, with Campylobacter infection being a notable contributor.

    Purpose of the Study:

    • To investigate the prevalence of Campylobacter in Russian patients diagnosed with IBS.
    • To explore the potential link between past AEI and the presence of Campylobacter in IBS patients.

    Main Methods:

    • Fecal samples were collected from 39 IBS patients.
    • Campylobacter detection was performed using three methods: bacterial culture, real-time PCR (polymerase chain reaction) with C. jejuni-specific primers, and ELISA (enzyme-linked immunosorbent assay).
    • Patient history regarding AEI was also considered.

    Main Results:

    • Only 7 out of 39 patients reported a history of AEI.
    • Campylobacter jejuni was identified in the stool of 2 patients (5% prevalence).
    • Detection methods varied: one patient tested positive by all three methods (with a history of AEI 30 years prior), while the second patient tested positive only by PCR, with subsequent confirmatory tests being negative.

    Conclusions:

    • Campylobacter jejuni was found in 5% of the studied IBS patients.
    • The findings underscore the need for further comprehensive studies on the gut microbiota in IBS patients.
    • Utilizing a combination of reliable microbiological and molecular techniques is recommended for future research in IBS.

    More Related Videos

    Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation08:34

    Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

    Published on: July 27, 2022

    Detection and Isolation of Campylobacter spp. from Raw Meat05:34

    Detection and Isolation of Campylobacter spp. from Raw Meat

    Published on: February 23, 2024

    Related Concept Videos

    Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

    Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

    Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
    Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
    Irritable Bowel Syndrome01:23

    Irritable Bowel Syndrome

    DefinitionIrritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent combinations of abdominal pain, bloating, diarrhea, or constipation.Pathophysiology of irritable bowel syndromeIts pathophysiology is multifactorial, involving disturbances in motility, sensory processing, microbial balance, barrier integrity, and gut–brain communication. These mechanisms interact to produce symptoms that vary across IBS subtypes.Altered Motility PatternsDisordered...
    Irritable Bowel Syndrome I: Introduction01:17

    Irritable Bowel Syndrome I: Introduction

    Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
    IBS is a chronic condition that can persist over a long period or recur frequently.
    The pathogenesis of IBS involves a complex interplay of the following factors:
    Altered...
    Chronic Bowel Disorders: Introduction01:17

    Chronic Bowel Disorders: Introduction

    Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
    Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
    Inflammatory Bowel Disease IV: Clinical Manifestations01:20

    Inflammatory Bowel Disease IV: Clinical Manifestations

    Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
    Drugs for Treatment of Diarrhea-Predominant IBS01:17

    Drugs for Treatment of Diarrhea-Predominant IBS

    Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
    Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...